Xylem (XYL) Stock Forecast & Price Target

Q: What analysts cover Xylem?

Xylem has been rated by research analysts at Barclays , Citigroup , CLSA , Jefferies Financial Group , JPMorgan Chase & Co. , Oppenheimer , Stifel Nicolaus , UBS Group , and Weiss Ratings in the past 90 days.

$118.22 +0.10 (+0.08%)

Closing price 07/2/2026 03:59 PM Eastern

Extended Trading

$118.00 -0.22 (-0.18%)

As of 07/2/2026 07:58 PM Eastern

Compare

Xylem - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 14 Analyst Ratings

Sell
0

Hold
6

Buy
8

Based on 14 Wall Street analysts who have issued ratings for Xylem in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 6 have given a hold rating, and 8 have given a buy rating for XYL.

Consensus Price Target

$153.54
29.88% Upside

According to the 14 analysts' twelve-month price targets for Xylem, the average price target is $153.54. The highest price target for XYL is $170.00, while the lowest price target for XYL is $133.00. The average price target represents a forecasted upside of 29.88% from the current price of $118.22.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for XYL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Xylem and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

XYL Analyst Ratings Over Time

Type	Current Forecast 7/5/25 to 7/5/26	1 Month Ago 6/5/25 to 6/5/26	3 Months Ago 4/6/25 to 4/6/26	1 Year Ago 7/5/24 to 7/5/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	10 Buy rating(s)	6 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$153.54	$152.77	$155.54	$143.71
Forecasted Upside	29.88% Upside	39.08% Upside	25.62% Upside	8.64% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

XYL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

XYL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Xylem Stock vs. The Competition

Type	Xylem	Business Services Companies	Broader Market
Consensus Rating Score	2.57	1.98	2.52
Consensus Rating	Moderate Buy	Reduce	Moderate Buy
Predicted Upside	29.88% Upside	338.64% Upside	13.30% Upside
News Sentiment Rating	Positive News See Recent XYL News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
6/25/2026	Jefferies Financial Group 2 of 5 stars	Stephen Volkmann Not Rated	Upgrade	Hold ➝ Buy	$130.00 ➝ $140.00	+24.94%
6/25/2026	CLSA 2 of 5 stars		Upgrade	Hold
5/8/2026	Weiss Ratings 5 of 5 stars		Downgrade	Hold (C+) ➝ Hold (C)
4/29/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Spector Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$132.00 ➝ $133.00	+14.40%
4/29/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bryan Blair Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$160.00 ➝ $158.00	+35.91%
4/29/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Grippin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$156.00 ➝ $154.00	+30.65%
4/29/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Kaplowitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$174.00 ➝ $168.00	+46.90%
4/29/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Nathan Jones Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$163.00 ➝ $159.00	+34.89%
4/16/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mark Strouse Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$170.00 ➝ $160.00	+27.80%
2/23/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Giordano Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold
Get the Latest News and Ratings for XYL and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Xylem and its competitors with MarketBeat's FREE daily newsletter.
2/11/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$158.00	+24.59%
2/11/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brett Linzey Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$138.00	+7.69%
2/11/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Halloran Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$161.00	+24.64%
2/11/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Deane Dray Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$176.00 ➝ $162.00	+28.53%
1/26/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Drab Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform
11/18/2025	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
10/29/2025	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$170.00	+10.94%
5/15/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bobby Zolper Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold
12/12/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brad Hewitt Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Peer Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:01 AM ET.

Should I Buy Xylem Stock? XYL Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, July 1, 2026. Please send any questions or comments about these Xylem pros and cons to contact@marketbeat.com.

Xylem
Bull Case

Here are some ways that investors could benefit from investing in Xylem Inc.:

Xylem Inc. reported earnings per share of $1.12 for the latest quarter, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
The company has a solid return on equity of 11.26%, suggesting effective management and profitability relative to shareholder equity.
With a recent revenue of approximately $2.12 billion, Xylem Inc. demonstrated a year-over-year revenue increase of 2.7%, reflecting resilience and growth in its operations.
Xylem Inc. has initiated a share repurchase plan authorizing the buyback of $1.50 billion in shares, which can signal to investors that the company believes its stock is undervalued and can enhance shareholder value.
The current stock price is around $117, which may present a buying opportunity for investors looking for growth in a stable industrial sector.

Xylem
Bear Case

Investors should be bearish about investing in Xylem Inc. for these reasons:

Despite positive earnings, the stock has seen price target reductions from several analysts, indicating potential concerns about future performance.
The dividend payout ratio is currently at 42.79%, which, while sustainable, may limit the company's ability to reinvest profits into growth opportunities.
Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy," suggesting that not all market participants are confident in its future performance.
Recent insider selling by the chief accounting officer could raise concerns about the company's internal confidence and future prospects.
Market volatility and economic uncertainties could impact Xylem Inc.'s performance, making it a riskier investment in the current climate.

XYL Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Xylem is $153.54, with a high forecast of $170.00 and a low forecast of $133.00.

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xylem in the last twelve months. There are currently 6 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" XYL shares.

According to analysts, Xylem's stock has a predicted upside of 29.88% based on their 12-month stock forecasts.

Over the previous 90 days, Xylem's stock had 3 upgrades and 3 downgrades by analysts.

Xylem has been rated by research analysts at Barclays, Citigroup, CLSA, Jefferies Financial Group, JPMorgan Chase & Co., Oppenheimer, Stifel Nicolaus, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like Xylem more than other "business services" companies. The consensus rating for Xylem is Moderate Buy while the average consensus rating for "business services" companies is Reduce. Learn more on how XYL compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Xylem Recommendations

This page (NYSE:XYL) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xylem (XYL) Stock Forecast & Price Target